Philips: Philips adds to its cardiology suite of solutions at ACC 2022 with innovations to help improve patient outcomes, experiences, and care pathway effectiveness

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new additions to its innovative integrated portfolio of cardiology solutions at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022). Philips’ cardiology portfolio offers solutions for coronary artery disease, structural heart disease, arrhythmia and heart failure. It integrates diagnostic and interventional imaging, treatment devices, and cardiac patient monitoring solutions at each point in the patient journey with the aim to improve clinical outcomes, patient and staff experiences, and care pathway effectiveness.



Cardiovascular disease continues to be the number one healthcare challenge globally and is one of the leading causes of death worldwide [1]. The costs associated with cardiovascular diseases are rising significantly, with an expected growth in cost of 101% by 2035 [2]. Worldwide, clinicians need to balance the delivery of high-quality care for a growing volume of complex patients with constantly improving departmental efficiency.



Adding to the strength and depth of its cardiology portfolio, at ACC.22 Philips is launching two major innovations. Philips Ultrasound Workspace, an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed via the web, allows clinicians to create seamless diagnostic workflows from the ultrasound exam room to the reporting room and beyond. Philips also announced the global availability of a new Ambient Experience solution connecting to Philips Image Guided Therapy System – Azurion, which aims to reduce patient anxiety during interventional procedures. Ambient Experience with FlexVision display offers patients a calming multi-sensory experience while staff prepare them for their procedure.